Memento Medicines is a biotech company dedicated to developing new therapies for patients with retinal diseases, focusing on novel antibody therapies
Memento Medicines is a biotech company dedicated to developing new therapies for patients with retinal diseases, focusing on novel antibody therapies. Its lead program, MMT-205, is a bispecific antibody that activates Tie2 and inhibits VEGF, aimed at treating neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).